Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity.
Breast cancer (BC) is a heterogeneous tumor, and better understanding of its heterogeneity is essential to improving treatment effect. Quantum dot (QD)-based immunofluorescent nanotechnology (QD-IHC) for molecular pathology has potential advantages in delineating tumor heterogeneity. This potential is explored in this paper by QD-IHC imaging of HER2 and ER. BC heterogeneity can be displayed more clearly and sensitively by QD-IHC than conventional IHC in BC tissue microarrays. Furthermore, the simultaneous imaging of ER and HER2 might help understand their interactions during the process of evolution of heterogeneous BC.
Chen
Chuang
C
Department of Oncology, Zhongnan Hospital of Wuhan University, Wuchang District, Wuhan, People's Republic of China.
Peng
Jun
J
Xia
Heshun
H
Wu
Qiongshui
Q
Zeng
Libo
L
Xu
Hao
H
Tang
Hongwu
H
Zhang
Zhiling
Z
Zhu
Xiaobo
X
Pang
Daiwen
D
Li
Yan
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism*; D003952:Diagnostic Imaging / Q000379:methods*; D005260:Female; D005455:Fluorescent Antibody Technique / Q000379:methods*; D018740:Genetic Heterogeneity; D006801:Humans; D008875:Middle Aged; D045663:Quantum Dots; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D046888:Tissue Array Analysis
D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human